Iryna Shatynska-Mytsyk

Iryna Shatynska-Mytsyk

Auto-generated profile, based on publicly available information

Iryna Shatynska-Mytsyk

Department of Radiology, Lviv National Medical University, Lviv, Ukraine

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2014 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
APAliye Aras Perk
Aliye Aras Perk
ISIryna Shatynska-Mytsyk
Iryna Shatynska-Mytsyk
YGYusuf Can Gercek
Yusuf Can Gercek
KBKadir Boztaş
Kadir Boztaş
MYMevzule Yazgan
Mevzule Yazgan
AFAmmad Farooqi
Ammad Farooqi
Progress in our understanding of molecular oncology has started to shed light on dysregulation of spatio-temporally controlled signaling pathways, inactivation of tumor suppressor genes, tumour and normal stem cell quiescence, overexpression of oncogenes, extracellular and stromal microenvironments, epigenetics and autophagy. Sequentially and characteristically it has been shown that cancer cells acquire the ability to escape from apoptotic cell death, proliferate uncontrollably, sustain angiogenesis and tactfully reconstitute intracellular pathways to avoid immune surveillance. We have attempted to provide a recent snapshot of most recent progress with emphasis on how rutin modulates wide ranging intracellular signaling cascades as evidenced by in-vitro and in-vivo research. It is worth describing that 'single-cell proteomics' analysis has further improved our understanding regarding intracellular signaling pathways frequently activated in cancer cells resistant to therapeutics and can provide biomarkers for cancer diagnosis and prognosis. Data obtained from preclinical studies will prove to be helpful for scientists to bridge basic and translational studies.

16 November 2016 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
YMYulian Mytsyk
Yulian Mytsyk
IDIhor Dutka
Ihor Dutka
YBYuriy Borys
Yuriy Borys
IKIryna Komnatska
Iryna Komnatska
ISIryna Shatynska-Mytsyk
Iryna Shatynska-Mytsyk
Peter KruzliakPeter Kruzliak
Peter Kruzliak

13 January 2016 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
AFAmmad Farooqi
Ammad Farooqi
SFSundas Fayyaz
Sundas Fayyaz
ISIryna Shatynska‐Mytsyk
Iryna Shatynska‐Mytsyk
ZJZeeshan Javed
Zeeshan Javed
SJSaima Jabeen
Saima Jabeen
PPPierluigi Benedetti Panici
Pierluigi Benedetti Panici

1 January 2014 in Polish Journal of Radiology
Verified
Journal Article
Open access
PDF file
ISIryna Shatynska-Mytsyk
Iryna Shatynska-Mytsyk
YMYulian Mytsyk
Yulian Mytsyk
YBYuriy Borys
Yuriy Borys
IKIryna Komnatska
Iryna Komnatska
IDIhor Dutka
Ihor Dutka
Diffusion-weighted imaging (DWI) is an MRI modality using strong bipolar gradients to create a sensitivity of the signal to the thermally-induced Brownian motions of water molecules and in vivo measurement of molecular diffusion. The apparent diffusion coefficient (ADC) is a quantitative parameter calculated from DWI images which is used as a measure of diffusion. DWI allows to obtain comprehensive information on morphological and functional state of the kidney during a single examination without contrast medium administration. The purpose of the study was to evaluate the value of DWI in differentiating benign and malignant solid kidney tumors based on the initial stage of the study. The study included 19 adult patients with pathologically verified renal tumors: 9 patients with clear cell subtype of the renal cell carcinoma, 5 patients with oncocytoma and 5 patients with angiomyolipoma (AML). In addition, 5 healthy volunteers with completely normal findings according to kidney ultrasound were included into this study and set as reference. All patients underwent renal MR imaging which included DWI with subsequent ADC measurement. MR imaging was performed with a 1.5 T body scanner using an eight-channel phased-array body coil. The mean ADC value of ccRCC was significantly lower than that of normal renal parenchyma (2.11±0.25×10(-3) mm(2)/s vs. 3.36±0.41×10(-3) mm(2)/s, p<0.01). There was a significant difference in ADC between the malignant and benign renal lesions: in patients with angiomyolipoma the ADC value was 2.36±0.32×10(-3) mm(2)/s vs. 2.11±0.25×10(-3) mm(2)/s; p<0.05 and in patients with oncocytoma - 2.75±0.27×10(-3) mm(2)/s vs. 2.11±0.25×10(-3) mm(2)/s; p<0.05. The difference in ADC values in patients with high and low ccRCC grades was observed. DWI can be used to characterize renal lesions; the ADC of a renal lesion can be potentially used as an additional parameter to help determine the appropriate clinical management.

23 October 2014 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
AAAliye Aras
Aliye Aras
MIMuhammed Javed Iqbal
Muhammed Javed Iqbal
SNSyed Kamran-Ul-Hassan Naqvi
Syed Kamran-Ul-Hassan Naqvi
YGYusuf Can Gercek
Yusuf Can Gercek
KBKadir Boztas
Kadir Boztas
AFAmmad Farooqi
Ammad Farooqi
Anticancer Activity of Essential Oils: Targeting of Protein Networks in Cancer Cells Essential oils;cancer;apoptosis;signaling; Cancer is a multifaceted and genomically complex disease and research over decades has gradually and sequentially shown that essential biological mechanisms including cell cycle arrest and apoptosis are deregulated. The benefits of essential oils from different plants have started to gain appreciation as evidenced by data obtained from cancer cell lines and xenografted mice. Encouraging results obtained from preclinical studies have attracted considerable attention and various phytochemicals have entered into clinical trials.

11 September 2015
Verified
Book Chapter
Closed access
PDF file
AFAmmad Farooqi
Ammad Farooqi
RSRubina Sohail
Rubina Sohail
SFSundas Fayyaz
Sundas Fayyaz
ISIryna Shatynska-Mytsyk
Iryna Shatynska-Mytsyk